Research programme: food allergy immunotherapeutics - Aimmune Therapeutics/Nestle Health Science

Drug Profile

Research programme: food allergy immunotherapeutics - Aimmune Therapeutics/Nestle Health Science

Alternative Names: Food allergy OIT - Aimmune Therapeutics; Food allergy oral immunotherapies - Aimmune Therapeutics

Latest Information Update: 04 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aimmune Therapeutics
  • Class Allergens; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Food hypersensitivity

Most Recent Events

  • 15 Mar 2017 Aimmune Therapeutics and Nestle Health Science agree to co-develop and co-commercialise food allergy therapies in USA for Food allergy
  • 03 Mar 2016 Aimmune Therapeutics plans to file an IND application with the US FDA for Food Allergy
  • 08 Sep 2015 Preclinical trials in Food allergy in USA (PO) before September 2015 (Aimmune Therapeutics Pipeline, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top